http://www.aktiencheck.de aktiencheck.de aktiencheck.de Sat, 25 Apr 2026 18:38:35 +0200 2 http://www.aktiencheck.de/forum/Genprex_Immunogene_Therapy_VS_NSCLC-A41L3N-t561683 http://www.aktiencheck.de/forum/Genprex_Immunogene_Therapy_VS_NSCLC-A41L3N-t561683 News, Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes&nbsp;AUSTIN, Texas — (January 4, 2023) —&nbsp;Genprex, Inc.&nbsp;(“Genprex” or the “Company”) (NASDAQ:&nbsp;GNPX), a&nbsp;clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators at the University of Pittsburgh will present preclinical data highlighting the therapeutic potential of Genprex’s gene therapy for Type 1 diabetes at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) being held February 22-25 in Berlin, Germany and online.“ATTD 2023 presents an ideal opportunity for the results of this important study to be presented to the diabetes community. The data further support the potential of Genprex’s novel gene therapy being devel [<a href="http://www.aktiencheck.de/forum/Genprex_Immunogene_Therapy_VS_NSCLC-A41L3N-t561683">mehr</a>]